ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide

Enrolling by invitationOBSERVATIONAL
Enrollment

94

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

August 30, 2026

Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
BEHAVIORAL

The 4A ProActive Management Model

This model focuses on four key areas - Active Education, Active Prevention Strategies, Active Management, and Active Follow-up. Active Education involves providing patients with detailed information on treatment regimens, potential AEs, and self-care through verbal education, reminder cards, and direct counseling. Active Prevention Strategies aims to directly reduce risks through nursing care bundles that incorporate supportive medications, fall risk assessments, and dietary guidance. Active Management establishes robust protocols for early AE reporting, rapid treatment, and standardized order sets. Active Follow-up comprises additional outpatient visits, patient surveys, medication refill coordination, and pharmacist/nurse follow-up calls to closely monitor patient adherence and symptoms.

Trial Locations (1)

510060

Affiliated Cancer Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Yonghong Li

OTHER